Daihan Pharmaceutical Co.,Ltd.
Financials
Valuation Metrics
Daihan Pharmaceutical Co.,Ltd.'s Market Cap is ₩1494B. At end of 2025 it was ₩1755B. Ranked #959 of 2,410 in KR market (top 40%), #467 of 1,631 on KOSDAQ (top 29%), #113 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 49%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 149.40B KRW | KR#959/2,410 Sec#113/231 |
| Revenue | 216.55B KRW | KR#984/2,410 Sec#54/231 |
| Net Income | 27.53B KRW | KR#589/2,410 Sec#35/231 |
| Total Assets | 347.66B KRW | KR#950/2,410 Sec#59/231 |
| Net Assets | 300.21B KRW | KR#715/2,410 Sec#46/231 |
| Employees | 675 | KR#371/2,410 Sec#30/231 |
| Value | ||
| P/E | 5.43x | KR#465/2,410 Sec#18/231 |
| P/B | 0.50x | KR#890/2,410 Sec#46/231 |
| P/S | 0.69x | KR#1,195/2,410 Sec#62/231 |
| EV/EBITDA | 3.50x | KR#146/2,410 Sec#3/231 |
| FCF Yield | 0.32% | KR#1,193/2,410 Sec#91/231 |
| Profitability | ||
| ROE | 9.17% | KR#685/2,410 Sec#46/231 |
| ROA | 7.92% | KR#446/2,410 Sec#34/231 |
| Op. Margin | 13.92% | KR#333/2,410 Sec#32/231 |
| Revenue Growth | 4.27% | KR#1,232/2,410 Sec#122/231 |
| Earnings Growth | -12.12% | KR#890/2,410 Sec#55/231 |
| Financial Health | ||
| Debt Ratio | 15.81% | KR#268/2,410 Sec#40/231 |
| Total Debt | 0 KRW | KR—/2,410 Sec—/231 |
| FCF | 481.5M KRW | KR#1,186/2,410 Sec#92/231 |
| Cash | 43.97B KRW | KR#800/2,410 Sec#50/231 |
| Current Ratio | 3.97x | KR#387/2,410 Sec#59/231 |
| Net Debt/EBITDA | -1.46x | KR#294/2,410 Sec#14/231 |
| Dividend | ||
| Div. Yield | 4.01% | KR#480/2,410 Sec#19/231 |
| Div. Growth | 11.11% | KR#569/2,410 Sec#32/231 |
| Performance | ||
| 1Y Return | -14.29% | KR#952/2,410 Sec#59/231 |
| 1M Return | -4.60% | KR#644/2,410 Sec#68/231 |
| From 52W High | -21.33% | KR#204/2,410 Sec#11/231 |
| 1Y MDD | -22.20% | KR#88/2,410 Sec#4/231 |
| Trading | ||
| Volume | 7,561 shares | KR#2,149/2,410 Sec#214/231 |
| Trading Value | 188.0M KRW | KR#1,507/2,410 Sec#158/231 |
| Foreign Own. | 20.24% | KR#223/2,410 Sec#10/231 |
| Per Share | ||
| EPS | 4,588 KRW | KR#234/2,410 Sec#14/231 |
| BPS | 50,036 KRW | KR#264/2,410 Sec#17/231 |
Company Info
Established in 1963 and listed on KOSDAQ in 1994, Daehan Pharm is a specialty pharmaceutical company manufacturing and selling infusion solutions. It primarily produces infusion solutions, ampoules, and nutritional solutions for medical facilities, and also enters the pharmacy market with OTC products like contact lens cleaning solutions. The company has established a mass production system and pursues cost reduction through continuous infrastructure development, including automated production lines and warehouses. Daehan Pharm's headquarters are located in Yeongdeungpo-gu, Seoul.